Beta-Blocker Therapy and Respiratory Considerations

Introduction to Beta-Blocker Selection

The European Society of Cardiology recommends beta-1 selective agents due to their more favorable side effect profile, particularly regarding respiratory symptoms 1, 2
Beta-1 selective blockers, such as metoprolol, atenolol, and bisoprolol, are commonly used and produce fewer respiratory symptoms in patients with asthma/COPD compared to non-selective agents 2

Nebivolol is a highly selective beta-1 blocker with additional vasodilatory properties related to nitric oxide modulation, which contributes to its favorable side effect profile 3, 4
Bisoprolol is a highly selective beta-1 blocker without vasodilatory properties and has a long half-life, allowing for once-daily dosing to achieve 24-hour efficacy 2

The American Heart Association suggests that beta-blockers with high beta-1 selectivity, like bisoprolol and nebivolol, are preferred in patients with bronchospastic airway disease requiring beta-blocker therapy 4, 5

Both bisoprolol and nebivolol have been proven effective in heart failure with reduced ejection fraction (HFrEF) 3, 6
Bisoprolol showed a 32% reduction in all-cause mortality in patients with NYHA class III or IV heart failure 3
Nebivolol significantly decreased the combined endpoint of all-cause mortality or cardiovascular hospital admissions in elderly patients with heart failure 3

The American Heart Association recommends bisoprolol or nebivolol for asthmatic patients with performance anxiety, as they are highly cardioselective beta-1 blockers that minimize bronchospasm risk while effectively managing performance anxiety symptoms 7, 8

Patients with classical pulmonary asthma may worsen their condition by using nonselective beta-blockers or agents with low beta-1 selectivity, according to the American College of Cardiology 7, 8
Non-selective beta-blockers cause worsening of bronchial asthma through increased airway resistance, as reported by the European Respiratory Society 7, 8
Atenolol should be avoided in asthmatic patients due to its low beta-1 selectivity, as stated by the National Asthma Council 8
Performance anxiety is listed as an indication for beta-blocker treatment, but non-selective agents like propranolol should be avoided in asthmatics, according to the American Academy of Allergy, Asthma, and Immunology 7, 9

The American College of Chest Physicians advises against using propranolol in asthmatic patients, as it is a non-selective beta-blocker that blocks both beta-1 and beta-2 receptors, significantly increasing bronchospasm risk 7, 8